A5084304704- Prostate Cancer Treatment and Research
- Bladder and Urothelial Cancer Treatments
- Cancer, Lipids, and Metabolism
- Radiopharmaceutical Chemistry and Applications
- Cancer Immunotherapy and Biomarkers
- Renal cell carcinoma treatment
- Urinary and Genital Oncology Studies
- Cancer Genomics and Diagnostics
- Economic and Financial Impacts of Cancer
- Multiple and Secondary Primary Cancers
- Hormonal and reproductive studies
- Ferroptosis and cancer prognosis
- Cancer-related molecular mechanisms research
- PARP inhibition in cancer therapy
- Cancer, Hypoxia, and Metabolism
- Renal and related cancers
- Mass Spectrometry Techniques and Applications
- Prostate Cancer Diagnosis and Treatment
- Global Cancer Incidence and Screening
- Health Systems, Economic Evaluations, Quality of Life
- Radiomics and Machine Learning in Medical Imaging
- Epigenetics and DNA Methylation
- Cancer Treatment and Pharmacology
- Forensic Toxicology and Drug Analysis
- Pneumonia and Respiratory Infections
University of Utah
2021-2025
Huntsman Cancer Institute
2021-2025
Detroit Medical Center
2024-2025
Wayne State University
2023-2025
Sinai Grace Hospital
2024
University of Utah Health Care
2022-2023
University of Louisville
2018-2021
Kempegowda Institute of Medical Sciences
2018
Accurate and efficient triage is crucial for prioritizing care managing resources in emergency rooms. This study investigates the effectiveness of ChatGPT, an advanced artificial intelligence system, assisting health providers with decision-making patients presenting metastatic prostate cancer, focusing on potential to improve both patient outcomes resource allocation.
Intensification of androgen deprivation therapy (ADT) with either docetaxel or receptor axis-targeted therapies (ARAT) are the current standard care for patients metastatic castration-sensitive prostate cancer (mCSPC). However, biomarkers guiding treatment selection lacking. We hypothesized that ADT intensification ARAT, but not docetaxel, would be associated improved outcomes in de novo (dn)-mCSPC harboring SPOP mutations.Patient-level data from a deidentified nationwide (U.S.-based)...
Importance The treatment paradigm for advanced urothelial carcinoma (aUC) has undergone substantial transformation due to the introduction of effective, novel therapeutic agents. However, outcomes remain poor, and little is known about current approaches attrition rates patients with aUC. Objectives To delineate evolving patterns in aUC using a US-based patient-level sample. Design, Setting, Participants This retrospective cohort study used data from nationwide deidentified electronic health...
Importance Targeted therapies based on underlying tumor genomic susceptible alterations have been approved for patients with metastatic prostate cancer (mPC) and advanced urothelial carcinoma (aUC). Objective To assess trends disparities in next-generation sequencing (NGS) testing among mPC aUC. Design, Setting, Participants This retrospective cohort study used an electronic health record–derived database to extract deidentified data of receiving care from US physician practices,...
Background: Both novel hormonal therapies and docetaxel are approved for treatment of metastatic prostate cancer (mPC; in castration sensitive or refractory settings). Present knowledge gaps include lack real-world data on patterns patients with newly diagnosed mPC, comparative effectiveness (NHT) versus after a prior NHT. Methods: Herein we extracted patient-level from large database mPC United States. Utilization NHT an alternate one was evaluated. Comparative examined via Cox proportional...
82 Background: Lu is a prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical that delivers beta radiation to PSMA-positive cells. It approved for pts with mCRPC who had prior progression on an androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy. However, there are limited real-world data the efficacy of based line therapy. Herein, we aimed assess survival outcomes receiving in setting. Methods: This retrospective study utilized nationwide Flatiron Health...
109 Background: C and Lu are associated with overall survival benefit approved for pts mCRPC after prior treatment docetaxel an androgen receptor pathway inhibitor (ARPI). However, in real-world settings, administering requires coordination across specialties resources [PMID: 36637862], which could delay its administration. Herein, we sought to compare the time from medication order first dose of versus Lu. Methods: This study used pt level data nationwide Flatiron Health electronic health...
100 Background: Metachronous mHSPC is associated with improved outcomes compared to synchronous (de novo) mHSPC. However, there are limited data on the effect of TTM after radical prostatectomy in patients metachronous treated systemic therapies. Our objective was explore association survival a real-world population. Methods: In this IRB-approved retrospective study, eligibility criteria were: pts who underwent and were ADT plus androgen receptor pathway inhibitor (ARPI). disease defined as...
PURPOSE The impact of insurance status on survival outcomes in patients receiving first-line systemic therapy for metastatic renal cell carcinoma (mRCC) has not been explored. Herein, we aimed to determine whether affects progression-free (PFS) and overall (OS) this setting. METHODS Patients diagnosed with mRCC between 1990 2022 from two National Cancer Institute–designated cancer centers available information were retrospectively identified using institutional databases. stratified by...
678 Background: Recent studies have suggested an association between the time-of-day of ICI infusions and disease outcomes, including progression free survival overall survival, among patients with cancer. (Qian et al Lancet Oncology 2021). We sought to identify whether such exists in mRCC receiving ICIs. Methods: Patients treated nivolumab alone, or combination ipilimumab, either first- second-line treatment were retrospectively identified. who received <25% after 4:30 pm assigned early...
Abstract Introduction Rechallenge with antibodies targeting programmed cell death protein‐1 or its ligand (PD‐1/L1) after discontinuation disease progression in solid tumors following a prior PD‐1/L1 treatment is often practiced clinic. This study aimed to investigate if adding inhibitors cabozantinib, the most used second‐line real‐world patients metastatic clear renal carcinoma (mccRCC), offers additional benefits. Methods Using de‐identified patient‐level data from large US‐based...
Androgen deprivation therapy (ADT) intensification (ADTi) (i.e., ADT with androgen receptor pathway inhibitor or docetaxel, both) has significantly improved survival outcomes of patients metastatic hormone-sensitive prostate cancer (mHSPC). However, the impact prior ADTi in mHSPC setting on disease presentation and castration-resistant (mCRPC) is not well characterized. In this study, our objective was to compare characteristics new mCRPC respect receipt intensified nonintensified setting.